Endokannabinoidnaya sistema: struktura i potentsial'nye vozmozhnosti v regulyatsii massy tela

1. Романцова Т.И., Волкова Г.Е. Лептин и грелин: антагонизм и взаимодействие в регуляции энергетического обмена. Ожирение и метаболизм. 2005;2:2-9.

2. Чурюканов.М.В., Чурюканов В.В. Функциональная организация и терапевтический потенциал эндогенной каннабиноидной системы. Экспериментальная и клиническая фармакология. 2004;67 (2):70-78.

3. Abel E.L. Cannabis:effects on hunger and thirst. Behav Biol. 1975;15:255-281.

4. Acosta-Urquidi J., Chase R. The effects of delta 9-tetrahydrocannabinol on action potentials in the mollusc Aplysia. Can. J. Physiol. Pharmacol. 1975;53:793-798.

5. Adams I.B., Martin B.R. Cannabis:pharmacology and toxicology in animals and humans. Addiction. 1996;91:1585-1614.

6. Anthenelli R.M., Despres J.P. Effects of rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US trial (smoking cessation in smokers motivated to quit). Proc Annual Meeting of the American College of Cardiology, New Orleans, LA, 2004.

7. Bacci A., Huguenard J.R., Prince D.A. Long-lasting self-inhibition of neocortical interneurons mediated by endocannabinoids. Nature. 2004;431:312-316.

8. Beal J.E., Olson R., Laubenstein L. et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995;10:89-97.

9. Bensaid M., Gary-Bobo M., Esclangon A., et al. The cannabinoid CB1 receptor antagonist SR141716 increases АсгрЗО mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol. 2003;63:908-914.

10. Bisogno Т., Howell F., Williams G., et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol. 2003;163:463-468.

11. Bisogno Т., Ventriglia M., Milone A. et al. Occurrence and metabolism of anandamide and related acyl-ethanolamides in ovaries of the sea urchin Paracentrotus lividus. Biochim. Biophys. Acta. 1998;1345:338-348.

12. Breivogel C.S, Griffin G., Di Marzo V., Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol. 2001;60:155-163.

13. Burdyga G., Lai S., Varro A., et al. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci. 2004;24:2708-2715.

14. Carlisle S.J., Marciano-Cabral F.,Staab A. et al. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol. 2002;2:69-82.

15. Corchero J., Fuentes J.A., Manzanares J. Chronic treatment with CP-55,940 regulates corticotropin releasing factor and proopiomelanocortin gene expression in the hypothalamus and pituitary gland of the rat. Life Sci. 1999;64:905-911.

16. Cota D., Marsicano G., Tschoep M., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112:423-131.

17. Cravatt B. F., Giang D. K., Mayfield S. P. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384:83-87.

18. Cravatt B.F., Demarest K., Patricelli M.P., et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA. 2001;98:9371-9376.

19. De Petrocellis L, Cascio M.G., Di Marzo V. The endocannabinoid system:a general view and latest additions. Br J Pharmacol. 2004;141:765-774.

20. De Petrocellis L., Melck D., Bisogno et al. Finding of the endocannabinoid signalling system in Hydra, a very primitive organism:possible role in the feeding response. Neuroscience. 1999;92:377-387.

21. Despres J.-P., Golay A., Sj_str_m L. for the Rimonabant in Obesity-Lipids Study Group Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. NEJM. 2005;353:2121-2134

22. Devane W.A., Dysarz F.A., Johnson M.R., et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34:605-613.

23. Devane W.A., Hanus L., Breuer A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946-1949.

24. Di Marzo V., Fontana A., Cadas H. et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons Nature. 1994;372:686-691.

25. Di Marzo V., Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura Gl, Palmiter RD, Sugiura T, Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001;410:822-825.

26. Di Marzo V., Matias I. Endocannabinoid control of food intake and energy balance. Nature Neuroscience. 2005;8(5):585-589.

27. Dinh T.P., Carpenter D., Leslie F.M. et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA. 2002;99:10819-10824.

28. Engeli S., Bohnke J., Feldpausch M., et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54:2838-2843.

29. Freedland C.S., Poston J.S., Porrino LJ. Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacol Biochem Behav. 2000;67:265-270.

30. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003;83:1017-1066.

31. Fride E., Ginzburg Y., Breuer A., et al. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol. 2001;419:207-214.

32. Gaoni Y., Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646-1647.

33. Gardner E.L., Vorel S.R. Cannabinoid transmission and rewardrelated events. Neurobiol Dis. 1998;5:502-533.

34. Giuffrida A., Beltramo M., Piomelli D. Mechanism of endocannabinoid inactivation:Biochemisry and pharmacology.J Pharmacol Exp Therapy. 2001;298:7-14.

35. Gomez R., Navarro M., Ferrer B. et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci. 2002;22:9612-9617.

36. Hanus L., Avraham Y., Ben-Shushan D. et al. Short-term fasting and prolonged semistarvation have opposite effects on 2-AG levels in mouse brain. Brain Res. 2003;983:144-151.

37. Hilairet S., Bouaboula M., Carriere D. et al. Hypersensitization of the orexin 1 receptor by the CB1 receptor:evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. J Biol Chem. 2003;278:23731-23737.

38. Howlett A.C., Barth F., Bonner T.I. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54:161-202.

39. Jarai Z., Wagner J.A., Varga K. et al. (1999) Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA. 1999;96:14136-14141.

40. Jbilo O., Ravinet-Trillou C, Arnone M. et al. The CB1 receptor antagonist rimonabant reverses the dietinduced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J. 2005;19:1567-1569.

41. Kirkham T.C., Williams CM. Endogenous cannabinoids and appetite. Nutr Res Reviews. 2001;14:65-86.

42. Liu Y.L., Connoley I.P., Wilson C.A., Stock M.J. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes Relat Metab Disord. 2005;29:183-187.

43. Maldonado R. Study of cannabinoid dependence in animals. Pharmacol Ther. 2002;95:153-164.

44. Martin B.R. Identification of the endogenous cannabinoid system through integrative pharmacological approach. J.Pharmacol.Exp.Ther. 2002;V.301, Issue 3:790-796.

45. Martin B. R., Wiley J.L. Mechanism of action of cannabinoids:how it may lead to treatment of cachexia, emesis and pain. J. Support Oncology. 2004;2:305-316.

46. Matsuda L.A., Lolait S.J., Brownstein M.J., et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (Lond). 1990;346:561-564.

47. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature (Lond). 1993;365:61-65.

48. Osei-Hyiaman D., DePetrillo M., Pacher P. et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115:1298-1305.

49. Pagotto U. The endocannabonoid system and the treatment of obesity. Annals of Medicine. 2005;37:270-275.

50. Pagotto U., Marsicano G., Cota D. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Reviews. 2006;27(1):73-100.

51. Peters H., Nahas G.G. A brief history of four millennia. In: Nahas G.G., Sutin K.M., Harvey D., Agurell S., eds. Marihuana and medicine. 1999, Totowa, NJ:Humana Press;3-7.

52. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003;4:873-884.

53. Ravinet-Trillou C., Delgorge C., Menet C. et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord. 2004;28:640-648.

54. Rowland N.E., Mukherjee M., Robertson K. Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology (Berl). 2001;159:111-116.

55. Rusk I.N., Cooper S.J. The selective dopamine D1 receptor agonist SK&F 38393:its effects on palatability- and deprivationinduced feeding, and operant responding for food. Pharmacol Biochem Behav. 1989;34:17-22.

56. Schwabe R.F. Endocannabinoids promote hepatic lipogenesis and steatosis through CB1 receptors. Hepatology. 2005;42:959-961.

57. Sepe N., De Petrocellis L., Montanaro F. et al. Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs:possible implications for mollusc physiology and sea food industry. Biochim. Biophys. Acta. 1998;1389:101-111

58. Shearman L.P., Zhou D., Rosko K.M. et al. Multiple day CB1R inverse agonist effects on hypothalamic gene expression and energy balance in dietinduced obese mice. Proc 34th Annual Meeting of the Society for Neuroscience, San Diego, CA, 2004 (Abstract 76.4)

59. Stella N. Cannabinoid signaling in glial cells. Glia. 2004;48:267-277.

60. Tucci S.A., Rogers E.K., Korbonits M., Kirkham T.C. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol. 2004;143:520-523.

61. Tzavara E.T., Perry K.W., Rodriguez D.E., et al. 2001 The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus. Eur J Pharmacol. 2001;426:R3-R4.

62. Van der Stelt M. The endocannabinoid anandamide. Metabolism and neuroprotection. Nederlands, Febo Enschede. 2002;9-40.

63. Van Gaal L.F., Rissanen A.M., Scheen A.J., et al. for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:1-year experience from the RIO-Europe study. Lancet. 2005;365:1389-1397.

64. Verty A.N., McFarlane J.R., McGregor I.S. et al. Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology. 2004;145:3224-3231.

65. Verty A.N., McGregor I.S., Mallet P.E. The dopamine receptor antagonist SCH 23390 attenuates feeding induced by 9-tetrahydrocannabinol. Brain Res. 2004;1020:188-195.

66. Volicer L., Stelly M., Morris J., et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 1997;12:913-919.

67. Williams C.M., Rogers P.J., Kirkham T.C. Hyperphagia in prefed rats following oral 9-THC. Physiol Behav. 1998;65:343-346.

68. Wilson R.I., Nicoll R.A. Endocannabinoid signaling in the brain. Science. 2002;296:678-682.

69. Wynne K., Stanley S., McGowan B., Bloom S. Appetite control. J Endocrinol. 2005;184:291-318.